SAR 402663
Alternative Names: SAR-402663Latest Information Update: 07 Jan 2025
Price :
$50 *
At a glance
- Originator Sanofi
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Wet age-related macular degeneration
Most Recent Events
- 07 Jan 2025 Phase-I/II clinical trials in Wet age-related macular degeneration in USA (Intravitreous) (NCT06660667)
- 28 Oct 2024 Sanofi plans a phase I/II trial for Wet age-related macular degeneration in November 2024 (Intravitreous) (NCT06660667)
- 28 Oct 2024 Preclinical trials in Wet-age-related macular degeneration in USA (Intravitreous)